252 related articles for article (PubMed ID: 6838557)
21. Degranulation of rabbit platelets with PAF-acether: a new procedure for unravelling the mode of action of platelet-activating substances.
Vargaftig BB; Joseph D; Marlas G; Chevance LG
Thromb Haemost; 1982 Aug; 48(1):67-71. PubMed ID: 7135345
[TBL] [Abstract][Full Text] [Related]
22. Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets.
Wade PJ; Lunt DO; Lad N; Tuffin DP; McCullagh KG
Thromb Res; 1986 Jan; 41(2):251-62. PubMed ID: 3961730
[TBL] [Abstract][Full Text] [Related]
23. Cooperation between platelets and neutrophils for paf-acether (platelet-activating factor) formation.
Coëffier E; Delautier D; Le Couedic JP; Chignard M; Denizot Y; Benveniste J
J Leukoc Biol; 1990 Mar; 47(3):234-43. PubMed ID: 2307906
[TBL] [Abstract][Full Text] [Related]
24. PAF-acether may not mediate the third pathway of platelet aggregation since self-desensitization reduces the effects of low thrombin but enhances those of convulxin.
Wal F; Joseph D; Touqui L; Vargaftig BB
Thromb Haemost; 1985 Feb; 53(1):99-104. PubMed ID: 3992525
[TBL] [Abstract][Full Text] [Related]
25. Metabolism of 1-alkyl-2-acyl-GPC in human platelets in response to stimulation by thrombin.
Alam I; Silver MJ
Thromb Res; 1987 Feb; 45(4):311-22. PubMed ID: 3576519
[TBL] [Abstract][Full Text] [Related]
26. The metabolism of 1-acyl-PAF in rabbit platelets and its possible interaction with PAF.
Touqui L; Silva CS; Vargaftig BB
Lipids; 1991 Dec; 26(12):992-6. PubMed ID: 1819755
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic study of PAF-acether. Preliminary results after the intravenous administration of a 3H-labelled product to the rabbit.
Lartigue-Mattei C; Godeneche D; Chabard JL; Berger JA
Agents Actions; 1982 Dec; 12(5-6):703-4. PubMed ID: 7164941
[TBL] [Abstract][Full Text] [Related]
28. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba.
Lamant V; Mauco G; Braquet P; Chap H; Douste-Blazy L
Biochem Pharmacol; 1987 Sep; 36(17):2749-52. PubMed ID: 2820421
[TBL] [Abstract][Full Text] [Related]
30. Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets.
Kloprogge E; de Haas GH; Gorter G; Akkerman JW
Thromb Res; 1983 Mar; 29(6):595-608. PubMed ID: 6222507
[TBL] [Abstract][Full Text] [Related]
31. Metabolism of platelet-activating factor in primary cultured adult rat hepatocytes by a new pathway involving phospholipase C and alkyl monooxygenase.
Okayasu T; Hoshii K; Seyama K; Ishibashi T; Imai Y
Biochim Biophys Acta; 1986 Mar; 876(1):58-64. PubMed ID: 3947669
[TBL] [Abstract][Full Text] [Related]
32. Biosynthesis of platelet-activating factor (PAF)acether). III. Formation of PAF-acether from synthetic substrates by stimulated murine macrophages.
Mencia-Huerta JM; Roubin R; Morgat JL; Benveniste J
J Immunol; 1982 Aug; 129(2):804-8. PubMed ID: 7086143
[TBL] [Abstract][Full Text] [Related]
33. Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets.
Adnot S; Joseph D; Vargaftig BB
Agents Actions; 1987 Jun; 21(1-2):195-202. PubMed ID: 3115070
[TBL] [Abstract][Full Text] [Related]
34. Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets.
Ostermann G; Till U; Thielmann K
Thromb Res; 1984 Feb; 33(4):409-18. PubMed ID: 6710440
[TBL] [Abstract][Full Text] [Related]
35. Lack of correlation between cytotoxicity of agonists and antagonists of platelet activating factor [paf-acether] in neoplastic cells and modulation of [3H]-paf-acether binding to platelets from humans in vitro.
Berdel WE; Korth R; Reichert A; Houlihan WJ; Bicker U; Nomura H; Vogler WR; Benveniste J; Rastetter J
Anticancer Res; 1987; 7(6):1181-7. PubMed ID: 3442414
[TBL] [Abstract][Full Text] [Related]
36. Effects of PAF-acether and structural analogues on platelet activation and bronchoconstriction in guinea-pigs.
Coëffier E; Borrel MC; Lefort J; Chignard M; Broquet C; Heymans F; Godfroid JJ; Vargaftig BB
Eur J Pharmacol; 1986 Nov; 131(2-3):179-88. PubMed ID: 3816952
[TBL] [Abstract][Full Text] [Related]
37. Inactivation of platelet activating factor by rabbit platelets. Lyso-platelet activating factor as a key intermediate with phosphatidylcholine as the source of arachidonic acid in its conversion to a tetraenoic acylated product.
Malone B; Lee T; Snyder F
J Biol Chem; 1985 Feb; 260(3):1531-4. PubMed ID: 3918041
[TBL] [Abstract][Full Text] [Related]
38. Platelet-activating factor (PAF-acether): thromboxane-independent synergism with adrenaline on human platelets and recent insights into its mode of action.
Fouque F; Joseph D; Vargaftig BB
Agents Actions; 1982 Dec; 12(5-6):720-2. PubMed ID: 7164947
[TBL] [Abstract][Full Text] [Related]
39. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds.
Baroggi N; Etienne A; Braquet P
Agents Actions Suppl; 1986; 20():87-97. PubMed ID: 3028108
[TBL] [Abstract][Full Text] [Related]
40. Kinetics of platelet-activating factor 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced fibrinogen binding to human platelets.
Kloprogge E; Mommersteeg M; Akkerman JW
J Biol Chem; 1986 Aug; 261(24):11071-6. PubMed ID: 3015954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
